A market analysis made by Moore Financial Consulting estimates the global market for Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the “Company” or “ZCT”), a FemTech medical device company advancing next-generation solutions for women’s health, will reach over USD 2 billion by 2030, with a compound annual growth rate of 5.25 per cent globally and 3.9 per cent in North America and 4.2 per cent in Europe.
The analysis emphasises that up to 75 per cent of women will have at least one vaginal yeast infection in their life.
Moreover, recurrent VVC (Vulvovaginal Candidiasis) affects nearly 8 per cent of women globally (for women above the ages of 15-60).
According to the data, 100 per cent of women with Recurrent VVC will purchase a combination of over-the-counter and prescription antifungal treatments, usually with the common use of oral agents.
Compared to women with non-recurrent VCC, 55.2 per cent will purchase prescription antifungal treatment, 37 per cent over-the-counter antifungal, 5.6 per cent will purchase a combination of both treatments, and the rest will not purchase any treatment.
Eli Ben Haroosh, founder & CEO, Zero Candida Technologies, said: “Moore’s market analysis matches our estimations, Zero Candida is a groundbreaking and game-changing company in the world of women’s medicine, and we look forward to be one of the leading companies offering AI-driven, tampon-like device, helping women suffering from VVC “.
Zero Candida announced recently that its shares are now successfully listed on the Frankfurt Stock Exchange (FSE).
This listing marks a significant milestone for the Company as it expands its global presence, now cross-listed on both the TSX Venture Exchange and the FSE, providing increased visibility and access to a broader pool of international investors.
